

# Pipeline

		Preclinical	Phase 1	Phase 2	Phase 3	Reg Filing	Market	
Prostate Cancer	PyL™ <sup>18</sup> F – PSMA-targeted PET imaging	█						
	aPromise - AI imaging analysis technology	█						
	1404 <sup>99m</sup> Tc <sup>1</sup> – PSMA-targeted SPECT	█						
	1095 <sup>131</sup> I – PSMA-targeted therapeutic	█						
	PSMA TTC <sup>227</sup> Th <sup>2</sup> – Alpha radionuclide	█						
Immuno-Oncology	NM-01 <sup>99m</sup> Tc <sup>3</sup> – anti-PD-L1 sdAb SPECT/CT	█						
Neuroendocrine	LMI 1195 <sup>18</sup> F – Cardiac PET imaging	█						
Brain	CarThera SonoCloud with Microbubble <sup>4</sup>	█						
	Insightec MRgFUS with Microbubble <sup>5</sup>	█						
Cardio/Vascular	Flurpiridaz <sup>18</sup> F <sup>6</sup> – Cardiac PET MPI	█						
	Cerevast Retinal Vein Occlusion Technology with Microbubble <sup>7</sup>	█						

<sup>1</sup>Licensed in Europe to ROTOP; <sup>2</sup>Clinical development program conducted by Bayer; <sup>3</sup>Ongoing Phase 1 clinical development conducted by NanoMab; <sup>4</sup>Clinical development program conducted by CarThera; <sup>5</sup>Clinical development program conducted by Insightec; <sup>6</sup>GE Healthcare is conducting the second Phase 3 study; <sup>7</sup>Clinical development program conducted by Cerevast.